Interleukin-6 modulated conditionally replicative adenovirus as an antitumor/cytotoxic agent for cancer therapy

Citation
C. Rancourt et al., Interleukin-6 modulated conditionally replicative adenovirus as an antitumor/cytotoxic agent for cancer therapy, CLIN CANC R, 5(1), 1999, pp. 43-50
Citations number
67
Categorie Soggetti
Oncology
Journal title
CLINICAL CANCER RESEARCH
ISSN journal
10780432 → ACNP
Volume
5
Issue
1
Year of publication
1999
Pages
43 - 50
Database
ISI
SICI code
1078-0432(199901)5:1<43:IMCRAA>2.0.ZU;2-U
Abstract
In this study, we report that an interleukin-6 (IL-6)-inducible E1A-substit uting activity can be exploited for the production of infectious adenoviral particles during infection with the E1A-deleted adenovirus (Ad) Ad5d1312, The basal level of complementation can be increased by 1.5 log by induction of the HepG2 cells with recombinant human IL-6, Additionally, the IL-6-ind ucible E1A-substituting activity can complement E1A deletion in other cance r cell lines to render them Ad producer cells on induction with recombinant human IL-6, although the efficiency of complementation varies between cell lines. Ad5d1312 can replicate in, produce cytotoxic effect, and kill human tumor cells without addition of exogenous IL-6 in the context of tumor cel ls possessing an IL-6 autocrine are, such as ovarian tumor cells. In contra st, normal human mesothelial cells isolated from normal human peritoneum li ning do not support replication of Ad5d1312, even in the presence of exogen ous IL-6, These results suggest that Ad5d1312 could be used as a cytotoxic agent to selectively kill tumor cells responsive to or possessing an IL-6 a utocrine arc.